Literature DB >> 1376331

Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.

B Felding-Habermann1, B M Mueller, C A Romerdahl, D A Cheresh.   

Abstract

Human melanoma originates in the skin and can lead to wide-spread metastatic disease. Analysis of melanoma biopsy material has shown that the vitronectin receptor, integrin alpha v beta 3, is a specific marker of the most malignant cells, i.e., vertically invasive primary lesions or distant metastases (Albelda, S. M., S. A. Mette, D. E. Elder, R. Stewart, L. Damjanovich, M. Herlyn, and C. A. Buck. 1990. Cancer Res. 50:6757-6764), suggesting a role for this adhesion receptor in the malignant growth of human melanoma tumors. A cell model was established to analyze the role of alpha v integrins on the tumorigenicity of human melanoma. From M21 human melanoma cells, stable variants were selected that lack alpha v gene expression and thus fail to express integrin alpha v beta 3 (M21-L cells). These cells not only lost the ability to attach to vitronectin but showed a dramatic reduction in tumorigenicity when transplanted into athymic nude mice, compared with M21 cells, even though both cell types showed identical beta 1 integrin expression and growth properties in vitro. M21-L cells were stably transfected with a cDNA-encoding alpha v. This resulted in the functional expression of integrin alpha v beta 3 on these cells and completely restored their tumorigenicity. Thus, integrin alpha v gene expression and the resulting adhesive phenotype are directly involved in the proliferation of human melanoma in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376331      PMCID: PMC295910          DOI: 10.1172/JCI115811

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells.

Authors:  B M Chan; N Matsuura; Y Takada; B R Zetter; M E Hemler
Journal:  Science       Date:  1991-03-29       Impact factor: 47.728

2.  Changes in integrin receptors on oncogenically transformed cells.

Authors:  L C Plantefaber; R O Hynes
Journal:  Cell       Date:  1989-01-27       Impact factor: 41.582

Review 3.  New perspectives in cell adhesion: RGD and integrins.

Authors:  E Ruoslahti; M D Pierschbacher
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

4.  Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells.

Authors:  F G Giancotti; E Ruoslahti
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

5.  Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor.

Authors:  D A Cheresh; R C Spiro
Journal:  J Biol Chem       Date:  1987-12-25       Impact factor: 5.157

6.  Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells.

Authors:  M J Humphries; K M Yamada; K Olden
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

7.  Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells.

Authors:  G Poste; J Doll; I J Fidler
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

8.  The integrin beta 1 subunit associates with the vitronectin receptor alpha v subunit to form a novel vitronectin receptor in a human embryonic kidney cell line.

Authors:  S C Bodary; J W McLean
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

9.  Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis.

Authors:  D A Cheresh; C J Honsik; L K Staffileno; G Jung; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

Review 10.  Cell surface molecules and tumor metastasis. Regulation of metastatic phenotypic diversity.

Authors:  G L Nicolson
Journal:  Exp Cell Res       Date:  1984-01       Impact factor: 3.905

View more
  117 in total

Review 1.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

Authors:  B P Eliceiri; D A Cheresh
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Arg-Tyr-Asp (RYD) and Arg-Cys-Asp (RCD) motifs in dendroaspin promote selective inhibition of beta1 and beta3 integrins.

Authors:  B Wattam; D Shang; S Rahman; S Egglezou; M Scully; V Kakkar; X Lu
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

Review 3.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

4.  Role of integrin alpha(v)beta3 in the early phase of liver metastasis: PET and IVM analyses.

Authors:  Hironori Kikkawa; Masako Kaihou; Natsuko Horaguchi; Takayuki Uchida; Hidetoshi Imafuku; Ayano Takiguchi; Yukako Yamazaki; Chieko Koike; Ryoko Kuruto; Takeharu Kakiuchi; Hideo Tsukada; Yoshikazu Takada; Nariaki Matsuura; Naoto Oku
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

5.  Protein kinase Cα (PKCα) regulates p53 localization and melanoma cell survival downstream of integrin αv in three-dimensional collagen and in vivo.

Authors:  Stephen D Smith; Martin Enge; Wenjie Bao; Minna Thullberg; Tânia D F Costa; Helene Olofsson; Behxhet Gashi; Galina Selivanova; Staffan Strömblad
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

6.  Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion.

Authors:  Gunjan Malik; Lynn M Knowles; Rajiv Dhir; Shuping Xu; Shuting Yang; Erkki Ruoslahti; Jan Pilch
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

7.  Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Authors:  Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma
Journal:  Lab Invest       Date:  2014-03-31       Impact factor: 5.662

8.  Synthesis and characterization of gadolinium-Peptidomimetic complex as an αvβ3 integrin targeted MR contrast agent.

Authors:  Young-Seung Kim; Yang Zhou; Henry Bryant; Diane E Milenic; Kwamena E Baidoo; Bobbi K Lewis; Joseph A Frank; Martin W Brechbiel
Journal:  Bioorg Med Chem Lett       Date:  2015-04-04       Impact factor: 2.823

9.  Expression order of alpha-v and beta-3 integrin subunits in the N-methyl-N-nitrosourea-induced rat mammary tumor model.

Authors:  Robabeh Rezaeipoor; Eric J Chaney; Amy L Oldenburg; Stephen A Boppart
Journal:  Cancer Invest       Date:  2009-06       Impact factor: 2.176

10.  Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

Authors:  Catherine Delbaldo; Eric Raymond; Karina Vera; Luz Hammershaimb; Karen Kaucic; Stéphanie Lozahic; Michel Marty; Sandrine Faivre
Journal:  Invest New Drugs       Date:  2007-09-18       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.